Patents by Inventor Riemke Van Dijkhuizen-Radersma

Riemke Van Dijkhuizen-Radersma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20230321261
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: September 30, 2022
    Publication date: October 12, 2023
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20200397913
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
    Type: Application
    Filed: June 3, 2020
    Publication date: December 24, 2020
    Inventors: Julia BOSHUIZEN, Kirstine JACOBSEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel Simon PEEPER, Henrik Jørn DITZEL, Paul PARREN
  • Antibodies binding AXL
    Patent number: 10765743
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: September 8, 2020
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20200199231
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 25, 2020
    Inventors: Patrick ENGELBERTS, Esther BREIJ, Rik RADEMAKER, Isil ALTINTAS, David SATIJN, Sandra VERPLOEGEN, Riemke VAN DIJKHUIZEN RADERSMA, Edward VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • ANTIBODIES BINDING AXL
    Publication number: 20200171152
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: November 4, 2019
    Publication date: June 4, 2020
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • Bispecific antibodies against CD3 and CD20
    Patent number: 10544220
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 28, 2020
    Assignee: GENMAB A/S
    Inventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren
  • Antibodies binding AXL
    Patent number: 10512688
    Abstract: The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: December 24, 2019
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • Antibodies binding AXL
    Patent number: 10500276
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: December 10, 2019
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • ANTIBODIES BINDING AXL
    Publication number: 20190275149
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: January 15, 2019
    Publication date: September 12, 2019
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • ANTIBODIES BINDING AXL
    Publication number: 20190160170
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: February 7, 2019
    Publication date: May 30, 2019
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • Antibodies binding AXL
    Patent number: 10201607
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 12, 2019
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20190022243
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20180326084
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 15, 2018
    Inventors: Julia BOSHUIZEN, Kirstine JACOBSEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Henrik Jørn DITZEL, Paul PARREN
  • ANTIBODIES BINDING AXL
    Publication number: 20180214549
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20170355767
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Application
    Filed: January 8, 2016
    Publication date: December 14, 2017
    Inventors: Patrick ENGELBERTS, Esther BREIJ, Rik RADEMAKER, Isil ALTINTAS, David SATIJN, Sandra VERPLOEGEN, Riemke VAN DIJKHUIZEN RADERSMA, Edward VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • ANTIBODIES BINDING AXL
    Publication number: 20170157250
    Abstract: The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 8, 2017
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • Controlled release compositions for interferon based PEGT/PBT block copolymers and method for preparation thereof
    Patent number: 8163307
    Abstract: The invention discloses a pharmaceutical composition for the controlled release of relatively toxic active compounds, in particular for bioactive proteins from the class of interferons. The composition comprises a biodegradable block copolymer constructed from poly(ethylene glycol) terephthalate (PEGT) and poly(butylene terephthalate) (PBT). The composition is provided in the form of injectable microparticles, of an injectable liquid which may have self-gelling properties, or of a solid implant. The invention further provides a pharmaceutical kit comprising the composition, methods for preparing the composition, and the pharmaceutical uses relating thereto.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: April 24, 2012
    Assignee: Biolex Therapeutics, Inc.
    Inventors: Anne Chantal Bechet, Riemke Van Dijkhuizen-Radersma, Martin Stigter, Jeroen Mattijs Bezemer
  • Controlled release compositions for interferon based on PEGT/PBT block copolymers and method for preparation thereof
    Patent number: 7867518
    Abstract: The invention discloses a pharmaceutical composition for the controlled release of relatively toxic active compounds, in particular for bioactive proteins from the class of interferons. The composition comprises a biodegradable block copolymer constructed from poly(ethylene glycol) terephthalate (PEGT) and poly(butylene terephthalate) (PBT). The composition is provided in the form of injectable microparticles, of an injectable liquid which may have self-gelling properties, or of a solid implant. The invention further provides a pharmaceutical kit comprising the composition, methods for preparing the composition, and the pharmaceutical uses relating thereto.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: January 11, 2011
    Assignee: Biolex Therapeutics, Inc.
    Inventors: Anne Chantal Bechet, Riemke Van Dijkhuizen-Radersma, Martin Stigter, Jeroen Mattijs Bezemer
  • Controlled release compositions for interferon based on PEGT/PBT block copolymers
    Patent number: 7736674
    Abstract: The invention discloses a pharmaceutical composition for the controlled release of relatively toxic active compounds, in particular for bioactive proteins from the class of interferons. The composition comprises a biodegradable block copolymer constructed from poly(ethylene glycol) terephthalate (PEGT) and poly(butylene terephthalate) (PBT). The composition is provided in the form of injectable microparticles, of an injectable liquid which may have self-gelling properties, or of a solid implant. The invention further provides a pharmaceutical kit comprising the composition, methods for preparing the composition, and the pharmaceutical uses relating thereto.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: June 15, 2010
    Assignee: Biolex Therapeutics, Inc.
    Inventors: Anne Chantal Bechet, Riemke Van Dijkhuizen-Radersma, Martin Stigter, Jeroen Mattijs Bezemer
  • Controlled Release Compositions for Interferon Based on PEGT/PBT Block Copolymers
    Publication number: 20100074868
    Abstract: The invention discloses a pharmaceutical composition for the controlled release of relatively toxic active compounds, in particular for bioactive proteins from the class of interferons. The composition comprises a biodegradable block copolymer constructed from poly(ethylene glycol) terephthalate (PEGT) and poly(butylene terephthalate) (PBT). The composition is provided in the form of injectable microparticles, of an injectable liquid which may have self-gelling properties, or of a solid implant. The invention further provides a pharmaceutical kit comprising the composition, methods for preparing the composition, and the pharmaceutical uses relating thereto.
    Type: Application
    Filed: November 25, 2009
    Publication date: March 25, 2010
    Applicant: BIOLEX THERAPEUTICS, INC.
    Inventors: Anne Chantal BECHET, Riemke VAN DIJKHUIZEN-RADERSMA, Martin STIGTER, Jeroen Mattijs BEZEMER